All In Biotech

NDA 050299 · Chartwell Molecules

Nilstat

Nystatin · Oral · Polyene Antifungal

Last checked: Nov 19, 2026Latest source record: Sep 23, 1999 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1971

Apr 14, 1971

Approved uses

1

Original approval plus efficacy supplements

Registered trials

56

16 Phase 3, 1 recruiting

FAERS reports

26,454

20,553 serious, 3,637 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 5, 2026.

INDICATIONS AND USAGE Nystatin oral suspension is indicated for the treatment of infections of the oral cavity caused by Candida albicans .

Therapeutic areas: Cardiovascular and metabolic · Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 14, 1971 Original approval
1 products under this application
  • NILSTAT · NYSTATIN 100,000 UNITS/ML · SUSPENSION, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Nystatin" as an intervention, any sponsor and status, largest first.

All 56 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea2,017
  • fatigue1,786
  • diarrhoea1,783
  • pneumonia1,643
  • dyspnoea1,487
  • off label use1,475
  • vomiting1,390
  • drug ineffective1,259
  • pain1,225
  • death1,152
  • pyrexia1,134
  • headache1,022

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004282
2005330
2006365
2007339
2008351
2009434
2010529
2011607
2012748
2013697
2014889
20151,327
20161,672
20171,666
20182,073
20192,196
20202,309
20211,793
20221,654
20231,690
20241,632
20251,651
20261,219

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 279 on PubMed

Sponsor: Chartwell Molecules

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.